Nemaura Medical Inc. (NASDAQ: NMRD) Is ‘One to Watch’
Nemaura’s flagship product, sugarBEAT(R), is a wearable, non-invasive and flexible Continuous Glucose Monitor (“CGM”) designed for people with diabetes and prediabetessugarBEAT received CE mark clearance in May 2019, allowing it to be marketed and sold within the European Union, and Nemaura has submitted a premarket approval application to the U.S. FDANemaura continues to build a world-class management teamNemaura plans to launch a direct to consumer…